Literature DB >> 17990085

Non-Bayesian knowledge propagation using model-based analysis of data from multiple clinical studies.

Jakob Ribbing1, Andrew C Hooker, E Niclas Jonsson.   

Abstract

The ultimate goal in drug development is to establish the manner of safe and efficacious administration to patients. To achieve this in an efficient way the information contained in the clinical studies should contribute to the increasing pool of accumulated knowledge. The aim of this simulation study is to investigate different knowledge-propagation strategies when the data is analysed using a model-based approach in NONMEM. Pharmacokinetic studies were simulated according to several scenarios of the underlying model and study design, including a population-optimal design based on analysis of a previous study. Five approaches with different degrees of knowledge propagation were investigated: analysing the studies pooled into one dataset, merging the results from analysing the studies separately, fitting a pre-specified model that has been selected from a previous study on either the most recent study or on the pooled dataset, or naïvely analysing the most recent study without any regards to any previous study. The approaches were evaluated on what model was selected (qualitative knowledge, investigated by stepwise covariate selection within NONMEM) as well as parameter precision (quantitative knowledge) and predictive performance of the model. Pooling all studies into one dataset is the best approach for identifying the correct model and obtaining good predictive performance and merging the results of separate analyses may perform almost as well. Fitting a pre-specified model on new data is fast, without selection bias, and sanctioned for model-based confirmatory analyses. However, fitting the same pre-specified model to all available data is still fast and can be expected to perform better in terms of predictive performance than the unbiased alternative. Using ED-optimal design of sample times and stratification of subjects from different subgroups is a successful strategy which allows sparse sampling and handles prior parameter uncertainty.

Entities:  

Mesh:

Year:  2007        PMID: 17990085     DOI: 10.1007/s10928-007-9079-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  32 in total

1.  Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets.

Authors:  E W Steyerberg; M J Eijkemans; F E Harrell; J D Habbema
Journal:  Stat Med       Date:  2000-04-30       Impact factor: 2.373

2.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

3.  POPED, a software for optimal experiment design in population kinetics.

Authors:  Marco Foracchia; Andrew Hooker; Paolo Vicini; Alfredo Ruggeri
Journal:  Comput Methods Programs Biomed       Date:  2004-04       Impact factor: 5.428

Review 4.  Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.

Authors:  Venkatesh A Bhattaram; Brian P Booth; Roshni P Ramchandani; B Nhi Beasley; Yaning Wang; Veneeta Tandon; John Z Duan; Raman K Baweja; Patrick J Marroum; Ramana S Uppoor; Nam Atiqur Rahman; Chandrahas G Sahajwalla; J Robert Powell; Mehul U Mehta; Jogarao V S Gobburu
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

5.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

6.  Model-based drug development: the road to quantitative pharmacology.

Authors:  Liping Zhang; Vikram Sinha; S Thomas Forgue; Sophie Callies; Lan Ni; Richard Peck; Sandra R B Allerheiligen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-13       Impact factor: 2.745

Review 7.  Drug interaction studies: study design, data analysis, and implications for dosing and labeling.

Authors:  S-M Huang; R Temple; D C Throckmorton; L J Lesko
Journal:  Clin Pharmacol Ther       Date:  2007-02       Impact factor: 6.875

8.  Use of prior information to stabilize a population data analysis.

Authors:  Per O Gisleskog; Mats O Karlsson; Stuart L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

9.  Bootstrap investigation of the stability of a Cox regression model.

Authors:  D G Altman; P K Andersen
Journal:  Stat Med       Date:  1989-07       Impact factor: 2.373

10.  How to select covariates to include in the analysis of a clinical trial.

Authors:  G M Raab; S Day; J Sales
Journal:  Control Clin Trials       Date:  2000-08
View more
  1 in total

1.  Informative study designs to identify true parameter-covariate relationships.

Authors:  Phey Yen Han; Carl M J Kirkpatrick; Bruce Green
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-03-27       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.